Ovarian Cancer and BRCA1/2 Testing: Opportunities to improve clinical care and disease prevention
Without prevention or screening options available, ovarian cancer is the most lethal malignancy of the female reproductive tract. High grade serous ovarian cancer (HGSOC) is the most common histologic subtype, and the role of germline BRCA1/2 mutation in predisposition and prognosis is established....
Main Authors: | Katherine eKarakasis, Julia eBurnier, Valerie eBowering, Amit eOza, Stephanie eLheureux |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2016-05-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2016.00119/full |
Similar Items
-
Tailoring Ovarian Cancer Treatment: Implications of <i>BRCA1/2</i> Mutations
by: Ainhoa Madariaga, et al.
Published: (2019-03-01) -
Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
by: Colombo I, et al.
Published: (2018-03-01) -
BRCA1 and BRCA2 and Inherited Predisposition to Breast and Ovarian Cancers
by: Patricia N. Tonin
Published: (2002-12-01) -
BRCA immunohistochemistry for screening of BRCA mutation in epithelial ovarian cancer patients
by: Tarinee Manchana, et al.
Published: (2020-08-01) -
Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcome
by: Ashour M, et al.
Published: (2019-07-01)